Results 201 to 210 of about 45,008 (286)

Sex Differences in Cancer Immunotherapy—Clinical Evidence and Mechanisms With a Focus on NSCLC

open access: yesImmunological Reviews, Volume 338, Issue 1, March 2026.
ABSTRACT Accumulating evidence suggests that the immune system shows subtle but relevant differences between men and women. These differences may have an impact on cancer development and TME composition as well as responses to and adverse events elicited by immunotherapies.
Eva Krieghoff‐Henning   +4 more
wiley   +1 more source

Effects of gonadectomy on brain sex hormone levels and amyloid pathology in male and female AppNL‐G‐F and AppNL‐F mice

open access: yesJournal of Neuroendocrinology, Volume 38, Issue 3, March 2026.
Abstract More women than men are diagnosed with Alzheimer's disease (AD). Sex hormones have been ascribed neuroprotective properties, and their decline, particularly the reduction of estrogen during menopause, has been implicated in AD risk. In this study, we examined how loss of circulating sex hormones affects cognitive performance and amyloid ...
Patricia Muñoz   +10 more
wiley   +1 more source

Sodium Phenylbutyrate Ameliorates Ovariectomy-Induced Bone Loss in Rats. [PDF]

open access: yesMedicina (Kaunas)
Akbaş B   +6 more
europepmc   +1 more source

Elevated Risk of Endometrial Cancer and Precursor Lesions in Patients With Myotonic Dystrophy: A Retrospective Study at a Single Institution in Japan

open access: yesJournal of Obstetrics and Gynaecology Research, Volume 52, Issue 3, March 2026.
ABSTRACT Aim Myotonic dystrophy (MD) has been associated with an increased risk of endometrial cancer (EC) in Western countries; however, data from Japan are limited. This study aimed to evaluate the incidence and clinical characteristics of EC and its precursor lesion, atypical endometrial hyperplasia (AEH), in Japanese patients with MD.
Ruka Hano   +9 more
wiley   +1 more source

Evaluating VEGFR2 as a Target for Anti‐Tumour Therapy in Canine Melanoma

open access: yesVeterinary and Comparative Oncology, Volume 24, Issue 1, Page 95-104, March 2026.
ABSTRACT Vascular endothelial growth factor receptor 2 (VEGFR2) is a key target for anti‐angiogenic oncotherapy, as inhibiting this receptor on tumour vasculature slows tumour development and enhances drug‐ and immune infiltration, improving therapy outcome.
Esther Hindriks   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy